.png)

Aggressive deal terms can kill a future raise when they only work in the optimistic exit case. Institutional allocators do not start with the $100M outcome; they test the $10M to $30M exit band first to see whether participating preferred, full ratchet anti-dilution, liquidation preferences, and existing investor rights still leave the founder, sponsor, and new capital properly aligned.
If the term structure makes ordinary outcomes unattractive, the raise becomes harder to underwrite before the investor evaluates the deal itself. Current investors may be over-rewarded, founders or sponsors may be structurally undermotivated, and incoming capital may need to negotiate around existing paper before it can commit.
The problem is that institutional allocators do not underwrite to the number that makes the deal look good. They test the $10M to $30M band first, because that is where most exits actually land, and because a term structure that only works at the optimistic case is not a structure at all.
Term structures that make a realistic exit unattractive signal to future capital that alignment was never the priority.
Three things happen when a cap table carries aggressive terms into a new raise:
The Capital Raise Pre-Flight is IRC Partners' fixed-fee diagnostic that scores a raise against the same twelve institutional gates a deal must clear before IRC Partners takes it into a strategic partnership. Going to market without that screen often surfaces these structural problems late, when they are already priced in as timeline and credibility loss. By the time an allocator flags them in a live process, the damage is already priced in as timeline and credibility loss.
Allocators test mediocre outcomes first. A deal that only makes sense at $100M requires everything to go right. Institutional mandates are built around ordinary results.
Here is how a 1x participating preferred with no cap plays out across three exit scenarios, assuming $10M raised at a $30M pre-money valuation with investors holding 25% of the common after conversion:
The $10M exit is the one that reveals the problem. At that number, the investor recovers the full preference and common holders receive nothing. Management, sponsors, and co-investors who hold common are structurally unmotivated at the most likely exit range.
Future investors see this table before they see your pitch deck. If prior paper over-rewards early capital in ordinary outcomes, the next round faces a harder underwriting problem: new money must compensate for the alignment deficit that already exists in the stack.
The $100M scenario is not a lie. It is just not the scenario that determines whether a deal is fundable.
Participating preferred is defensible in narrow contexts. In early-stage deals with genuine binary risk, it holds. The problem is context and degree.
When participating preferred shows up in a mainstream institutional round, or in a real estate preferred equity structure where exit values are more predictable, it reads differently. It reads as a signal that the investor did not trust the deal enough to accept standard non-participating terms, and that the sponsor did not have enough leverage to push back.
The deeper issue is what the term says about the next round. Incoming institutional capital is not just evaluating the deal. It is evaluating whether the existing paper leaves room for clean new money. Uncapped participating preferred on prior rounds often forces new investors to negotiate a restructure before they can commit, which adds months to a 4 to 9 month raise timeline and sometimes kills the round entirely.
Two anti-dilution mechanisms exist. Weighted average adjusts the conversion price based on the size and price of the down round. Full ratchet resets the conversion price to the new lower price entirely, as if every prior dollar had invested at the worst price. The ownership difference is significant.
Assume an investor puts in $5M at $1.00 per share, receiving 5 million shares. A subsequent round prices at $0.50 per share.
The full ratchet scenario doubles the investor's share count without any additional capital. Every other shareholder, including the new round's investors, absorbs that dilution.
Sophisticated allocators read full ratchet as a distress signal, not a negotiating win. It tells them the prior round expected weak pricing support, or that the sponsor had no leverage to negotiate a market-standard weighted average clause. Either reading reduces confidence in the deal's trajectory.
The clause does not even need to be triggered to cause damage. Incoming investors know that a full ratchet sitting on the cap table is a loaded mechanism. If the next round prices lower, the ownership math becomes unpredictable. That uncertainty gets priced into the terms new investors demand, or it becomes the reason they pass entirely.
Weighted average anti-dilution, by contrast, is standard in institutional rounds and rarely draws scrutiny. The presence of full ratchet, in a growth-stage or institutional context, is almost always worth flagging before a new raise opens.
{{main-cta}}
Allocators are not reading your term sheet to understand your history. They are reading it to decide whether you understand alignment. The terms you accepted in a prior round are evidence of how you negotiate, how you think about future capital, and whether you optimized for closing quickly over building a financeable structure.
When an allocator sees aggressive terms in the existing cap table, they typically draw one of three inferences:
These are underwriting inputs. The allocator's question is whether they can underwrite a clean position into this stack and whether this team will make decisions that protect their capital's long-term position.
If the answer to either question is uncertain, the deal gets slower. Mandate alignment becomes harder when the cap table itself is a variable that needs solving before the deal can be evaluated on its merits. That is why mandate alignment is evaluated alongside term structure, not after it.
Every term in the existing cap table should pass three screens before a new raise opens.
A structured pre-raise diagnostic runs all 12 categories, including term structure and cap table alignment, and returns a scored 0 to 100 readiness assessment in 10 business days. Deals scoring below 85 typically surface at least one structural issue that would slow or stop a live raise.
Term structure is one gate. The others matter equally. Understanding whether a pass or not-yet verdict is coming before you go to market is the difference between a 4 to 9 month raise and one that never closes. Understanding why institutional raises fail covers all 12 of those gates, not just the term sheet.
Uncapped participating preferred on prior rounds adds friction to every subsequent raise, typically 60 to 90 days of additional timeline as allocators underwrite around existing paper. Institutional allocators need to underwrite around existing paper before they can evaluate new money, and that process can add 60 to 90 days to a raise that was already 4 to 9 months long. Whether it kills the deal depends on the exit math at realistic values, not the optimistic case.
Full ratchet resets the conversion price of prior shares to the new lower price entirely, regardless of round size, which can double or triple prior investors' share counts after a single down round. Weighted average adjusts the conversion price proportionally based on the size and price of the down round, producing a more moderate ownership shift. Institutional allocators treat weighted average as standard and full ratchet as a distress signal.
Participating preferred typically becomes a structural problem below the 3x return threshold on invested capital. In a deal with $10M raised on 1x participating preferred, any exit below roughly $30M leaves common holders competing with the preference recovery plus participation, which can reduce or eliminate their proceeds. The $10M to $30M exit band is where most deals actually land, making this the critical test range.
Yes, prior terms can be amended, but the process requires existing investor consent and often involves economic trade-offs. Common remedies include converting participating preferred to non-participating, adding or lowering a participation cap, or replacing full ratchet with weighted average anti-dilution. Each amendment negotiation adds time and signals to incoming investors that the cap table required repair, which is its own due diligence flag.
Institutional allocators review cap tables and prior term sheets across 12 screening categories, evaluating term structure alongside mandate alignment, financial model quality, and management track record. Term structure is evaluated alongside mandate alignment, financial model quality, and management track record. A deal that passes on fundamentals but carries aggressive prior paper often receives a not-yet verdict rather than a pass, with the expectation that the structure gets cleaned up before re-engagement.
Yes. A readiness score built across 12 categories includes cap table structure, liquidation preference mechanics, and anti-dilution provisions as scored inputs. Deals scoring below 85 on a 0 to 100 scale typically carry at least one structural issue in these categories. The score is a diagnostic of whether the deal is structurally ready to enter a live raise without avoidable friction.
A structured pre-raise diagnostic covering term structure, cap table alignment, and 10 other institutional readiness categories takes 10 business days and produces a 20 to 30 page report scored from 0 to 100. That report gives sponsors and founders a clear picture of which structural issues will surface in live diligence before they spend months in a raise that stalls on solvable problems.
You get one shot to raise the right way. If this raise is worth doing, it’s worth doing with precision, leverage, and control.
This isn’t a practice run. Serious capital. Serious strategy. Let’s raise it right.
We onboard a maximum of seven
new strategic partners each quarter, by application only, to maximize your chances of securing the capital you need.